Please assess the completion status of the following clinical trial:

Trial Title: A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 years to 80 years.~* Subjects must have documented evidence of a history of atherosclerotic coronary artery disease/surgical revascularization.~* Subjects on a stable medication regimen.~* Body weight 50 kg or greater at screening.~Exclusion Criteria:~* Moderate/severe heart failure or renal impairment.~* Uncontrolled hyperglycemia in subjects with type 1 or type 2 diabetes.~* Receipt of the combination of omeprazole and clopidogrel within 1 month of randomization.~* Subjects whose medical history, condition or medication regimen may interfere with the evaluation of the safety and tolerability of CSL112 (for example significantly altered electrocardiogram (ECG) waveform, hepatobiliary disease, malignancy, thrombocytopenia, etc.)~* Known hypersensitivity to the product components

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CSL112 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).